NVAX
NovavaxBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
NVAX vs peer average
50/100
NVAX vs. peer average (B vs. B)
Grade spread
A 2 · B 7 · D 1
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ANAB is the first available peer comparator.
AnaptysBio is a closer small-cap biotech valuation comp than a business-model comp; it helps frame how the market discounts cash-backed pipeline optionality, but it is not a vaccine royalty story.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
NVAX
Novavax
ANAB
AnaptysBio
Grade
B
A
Momentum
88
95
Value
60
41
Sentiment
32
53
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ANAB
NVAX / ANAB
Grade Position
In line
NVAX vs. peer average (B vs. B)
50/100
Momentum
88
ANABValue
60
NVAXSentiment
32
ANABRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs NVAX
ANAB is the first peer returned for this comparison set.